Replies to post #103922 on Biotech Values

[Shengli]

Idenix is exciting for similar reasons. It will be presenting a combination study of two of its antiviral drugs at the AASLD

Considering it was published today makes one wonder

[DewDiligence]

(ZGEN)—From the same article:

Biotech Stock Research Chief Executive David Miller, who had listed ZymoGenetics as one of the top picks in his monthly newsletter, argues that ZymoGenetics was "gutless" and "math-challenged" for taking the Bristol deal. He pointed out that ZymoGenetics could have made as much as $1.1 billion from its pre-existing Bristol collaboration without the merger…

It’s disgraceful that Miller has to say stuff like this to placate subscribers. The probability that ZGEN would have earned the entire set of Lambda milestone payments—of which about one-third pertained to HBV rather than HCV—is close to nil, IMO.